1. X
  2. OncoAlert
Log inSign up
OncoAlert
123.3K posts
Image
user avatar
OncoAlert
@OncoAlert
🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
OncoAlert360.com
Joined March 2019
137
Following
42.1K
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • Pinned
    user avatar
    OncoAlert
    @OncoAlert
    Jul 17
    Does deeper HIF-2α suppression mean better outcomes in Refractory Clear Cell #KidneyCancer? We are here with another #WeekInOncology and no other than our faculty Natalia Gandur from Argentina🇦🇷 to guide us through this great publication Casdatifan shows durable response
    Image
    00:00
    3.2K03.2K
  • OncoAlert reposted
    user avatar
    Hidehito HORINOUCHI
    @HHorinouchi
    28m
    🔥Comparison of ctDNA assays for MRD detection in NSCLC 🆙 @JTOonline ☑Tumor-naïve vs tumor-informed fixed vs personalized panel 🎯Personalized assay: sensitivity 40.9%, specificity 100% 🎯MRD+ predicts shorter DFS (HR 13.98); 7-mo lead time 🎙Dr. Qian Cui #LCSM #LiquidBiopsy
    Image
    1140114
  • OncoAlert reposted
    user avatar
    Hidehito HORINOUCHI
    @HHorinouchi
    14m
    🔥DART: Durvalumab + RT (without chemo) in cCRT-ineligible LA-NSCLC 🆙 @JCO_ASCO ☑Phase 2; met primary endpoint: 2-y PFS 39% vs historical 20% 🎯2-y OS 54%; PD-L1+ & better PS associated with improved outcomes 🎙Dr. Andreas Rimner #LCSM @OncoAlert @Larvol
    Image
    ascopubs.org
    Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung...
    PURPOSEConcurrent platinum-based chemotherapy and radiation therapy (cCRT) followed by consolidative durvalumab is the standard of care (SoC) for fit patients with inoperable, locally advanced...
    85085
  • OncoAlert reposted
    user avatar
    Mirrors of Medicine
    @mirrorsmed
    2h
    The 10-year RAPCHEM results add to growing evidence that one-size-fits-all radiotherapy may no longer be necessary after primary systemic therapy. Tailoring radiotherapy in cT1–2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up
    Image
    1740174
  • OncoAlert reposted
    user avatar
    Advanced Prostate Cancer Consensus Conference
    @APCCC_Lugano
    3h
    Could calling Gleason 6 "precancer" instead of "cancer" actually save lives? Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous (Brief Report out on JAMA Oncology) This decision-analysis study modeled the effects of relabeling Grade Group 1
    Image
    4800480
  • OncoAlert reposted
    user avatar
    Nieves Martinez Lago MD PhD
    @DraMartinezLago
    1h
    📊 Periop CT + ICI in GEA 🔎 Systematic review, 30 RCTs (N=11,453) 📈 EFS strongly correlated with OS 🎯 R = 0.83 ✅ Correlation remained robust across sensitivity analyses 💡 Strong evidence supporting EFS as a surrogate endpoint for OS. 🔗 doi.org/10.1016/j.esmo… @OncoAlert
    Image
    Image
    Image
    Image
    3320332
  • user avatar
    OncoAlert
    @OncoAlert
    2h
    Could a lung transplant become a treatment option for carefully selected patients with stage IV lung cancer? New data are challenging one of oncology’s long-standing assumptions. Lung Transplant for Refractory Lung-Limited Stage IV Non–Small Cell Lung Cancer out on JAMA This
    Image
    4720472
    user avatar
    OncoAlert
    @OncoAlert
    2h
    Article:
    Image
    Lung Transplant for Lung Cancer
    From jamanetwork.com
    1880188
  • OncoAlert reposted
    user avatar
    Yüksel Ürün
    @DrYukselUrun
    Jul 19
    Replying to @VincentRK @NEJM and 2 others
    This study reminded me of the landmark 2010 ECOG trial. It started with a simple patient question: “Do we really need this much dexamethasone?” Today we’re asking another: “Do we really need longer maintenance?” Some of the biggest advances in oncology come from questioning “more
    Image
    2600260
  • OncoAlert reposted
    user avatar
    Erman Akkus
    @Erman_Akkus
    21h
    🔴Cancer-associated thrombosis in GI cancers #cancer #oncology #MedX #GI @OncoAlert
    Image
    Made with AI
    2.3K02.3K
  • OncoAlert reposted
    user avatar
    Marianna Valzano
    @MariValzano
    5h
    📢Registration is open for #FlorenceConsensus26. Join leading experts in Florence, 9–10 Oct 2026, for a Multidisciplinary Consensus on the integration of radiotherapy with new systemic treatments. ⏰Free registration | 100 places available. @OncoAlert
    Image
    2940294
  • OncoAlert reposted
    user avatar
    Uğur Özkerim
    @UOzkerim
    Jul 19
    ⁉️ Can adding ipilimumab overcome resistance after progression on nivolumab in recurrent/metastatic HNSCC? The phase II OPTIM trial addressed this question and found no evidence of benefit with nivolumab–ipilimumab. Docetaxel achieved higher ORR (17.6% vs 0%) and longer PFS
    Image
    Image
    2.3K02.3K
  • OncoAlert reposted
    user avatar
    Emre Yekedüz
    @yekeduz_emre
    Jul 19
    Proud to share our new publication from the @EAUYAU_RenalCa EAU Young Academic Urologists (YAU) Renal Cancer Working Group, a great collaborative effort exploring where evidence ends and expert consensus begins in renal cell carcinoma, with key insights from @AUC3_Official 2025.
    Image
    1.2K01.2K
  • OncoAlert reposted
    user avatar
    Uğur Özkerim
    @UOzkerim
    Jul 19
    Real-world evidence for T-DXd in HER2-mutant NSCLC is encouraging. In the multinational TRACER/HERTras cohort (n=168): 🔹 ORR: 55% 🔹 mPFS: 7.2 months 🔹 Intracranial ORR: 74% Patients with active brain metastases were also included, reinforcing the intracranial activity of
    Image
    1.5K01.5K
  • OncoAlert reposted
    user avatar
    Vincent Rajkumar
    @VincentRK
    Jul 18
    MyelomaRisk.com One-stop free-to-use website to risk stratify myeloma, MGUS, smoldering myeloma, Waldenstroms Macroglobulinemia, Amyloidosis. Also links to iStopMM calculator to determine when a bone marrow is needed in MGUS. Will be regularly updated. More
    MyelomaRisk risk calculator preview
    MyelomaRisk - Myeloma Risk Calculator
    From myelomarisk.com
    5K05K
Advertisement
Advertisement